Recro Pharma, Inc. (NASDAQ:REPH) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $9.93 and last traded at $9.64, with a volume of 225200 shares traded. The stock had previously closed at $9.68.
Several research analysts recently issued reports on REPH shares. Zacks Investment Research upgraded shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $8.25 target price for the company in a research report on Wednesday, August 16th. Piper Jaffray Companies restated a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a research report on Friday, October 27th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $11.65.
The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp purchased a new stake in Recro Pharma during the first quarter valued at about $156,000. KCG Holdings Inc. bought a new position in shares of Recro Pharma during the first quarter valued at about $173,000. JPMorgan Chase & Co. raised its stake in shares of Recro Pharma by 183.4% during the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after acquiring an additional 14,098 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Recro Pharma by 76.9% during the second quarter. Janney Montgomery Scott LLC now owns 22,085 shares of the specialty pharmaceutical company’s stock valued at $155,000 after acquiring an additional 9,600 shares during the last quarter. Finally, Teachers Advisors LLC bought a new position in shares of Recro Pharma during the second quarter valued at about $162,000. Institutional investors and hedge funds own 61.55% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Recro Pharma (REPH) Hits New 12-Month High at $9.93” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://sportsperspectives.com/2017/12/03/recro-pharma-reph-hits-new-12-month-high-at-9-93.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.